ARMATA PHARMACEUTICALS, INC. Revenue Not from Contract with Customer
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Revenue Not from Contract with Customer of $2.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RevenueNotFromContractWithCustomer · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. revenue not from contract with customer for the quarter ending 2026-06-30 was $2.51M, a 15.72% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. revenue not from contract with customer for the quarter ending 2026-03-31 was $789.00K, a 60.69% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. revenue not from contract with customer for the quarter ending 2025-12-31 was $1.08M, a 12.15% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. revenue not from contract with customer for the quarter ending 2025-09-30 was $1.16M, a 61.02% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. revenue not from contract with customer for fiscal 2025 was $4.90M, a 5.22% decline from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. revenue not from contract with customer for fiscal 2024 was $5.17M, a 14.24% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. revenue not from contract with customer for fiscal 2023 was $4.53M, a 17.77% decline from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. revenue not from contract with customer for fiscal 2022 was $5.51M, a 23.11% increase from fiscal 2021.
| Period end | Revenue Not from Contract with Customer 3 month | Revenue Not from Contract with Customer 6 month | Revenue Not from Contract with Customer 9 month | Revenue Not from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.51M 10-Q · filed 2026-08-12 | $3.30M 10-Q · filed 2026-08-12 | $4.38M derived: sum of 3 quarters · filed 2026-08-12 | $5.54M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $789.00K 10-Q · filed 2026-05-13 | $1.87M derived: sum of 2 quarters · filed 2026-05-13 | $3.03M derived: sum of 3 quarters · filed 2026-05-13 | $5.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.24M derived: sum of 2 quarters · filed 2026-03-25 | $4.41M derived: sum of 3 quarters · filed 2026-08-12 | $4.90M 10-K · filed 2026-03-25 |
| 2025-09-30 | $1.16M 10-Q · filed 2025-11-12 | $3.33M derived: sum of 2 quarters · filed 2026-08-12 | $3.82M 10-Q · filed 2025-11-12 | $5.05M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.17M 10-Q · filed 2026-08-12 | $2.66M 10-Q · filed 2026-08-12 | $3.90M derived: sum of 3 quarters · filed 2026-08-12 | $6.87M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $491.00K 10-Q · filed 2026-05-13 | $1.73M derived: sum of 2 quarters · filed 2026-05-13 | $4.70M derived: sum of 3 quarters · filed 2026-05-13 | $4.70M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.21M derived: sum of 2 quarters · filed 2026-03-25 | $4.21M derived: sum of 3 quarters · filed 2026-03-25 | $5.17M 10-K · filed 2026-03-25 |
| 2024-09-30 | $2.97M 10-Q · filed 2025-11-12 | $2.97M derived: sum of 2 quarters · filed 2025-11-12 | $3.94M 10-Q · filed 2025-11-12 | $5.47M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $966.00K 10-Q · filed 2025-08-12 | $2.49M derived: sum of 3 quarters · filed 2025-08-12 | $3.72M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $966.00K 10-Q · filed 2025-05-14 | $2.49M derived: sum of 2 quarters · filed 2025-05-14 | $3.72M derived: sum of 3 quarters · filed 2025-05-14 | $4.70M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $2.75M derived: sum of 2 quarters · filed 2025-03-21 | $3.73M derived: sum of 3 quarters · filed 2025-03-21 | $4.53M 10-K · filed 2025-03-21 |
| 2023-09-30 | $1.23M 10-Q · filed 2024-11-13 | $2.21M derived: sum of 2 quarters · filed 2024-11-13 | $3.00M 10-Q · filed 2024-11-13 | $4.05M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $980.00K 10-Q · filed 2024-08-13 | $1.78M 10-Q · filed 2024-08-13 | $2.83M derived: sum of 3 quarters · filed 2024-08-13 | $4.17M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $796.00K 10-Q · filed 2024-05-07 | $1.85M derived: sum of 2 quarters · filed 2024-05-07 | $3.19M derived: sum of 3 quarters · filed 2024-05-07 | $5.07M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.39M derived: sum of 2 quarters · filed 2024-03-21 | $4.27M derived: sum of 3 quarters · filed 2024-03-21 | $5.51M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.34M 10-Q · filed 2023-11-14 | $3.22M derived: sum of 2 quarters · filed 2023-11-14 | $4.46M 10-Q · filed 2023-11-14 | $5.45M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.88M 10-Q · filed 2023-08-14 | $3.12M 10-Q · filed 2023-08-14 | $4.11M derived: sum of 3 quarters · filed 2023-08-14 | $5.36M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.24M 10-Q · filed 2023-05-11 | $2.23M derived: sum of 2 quarters · filed 2023-05-11 | $3.48M derived: sum of 3 quarters · filed 2023-05-11 | $4.64M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $989.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $2.24M derived: sum of 2 quarters · filed 2023-03-16 | $3.41M derived: sum of 3 quarters · filed 2023-03-16 | $4.47M 10-K · filed 2023-03-16 |
| 2021-09-30 | $1.25M 10-Q · filed 2022-11-09 | $2.42M derived: sum of 2 quarters · filed 2022-11-09 | $3.48M 10-Q · filed 2022-11-09 | $3.99M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.17M 10-Q · filed 2022-08-11 | $2.23M 10-Q · filed 2022-08-11 | $2.74M derived: sum of 3 quarters · filed 2022-08-11 | $3.03M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $1.07M 10-Q · filed 2022-05-12 | $1.57M derived: sum of 2 quarters · filed 2022-05-12 | $1.86M derived: sum of 3 quarters · filed 2022-05-12 | $1.89M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $504.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $792.00K derived: sum of 2 quarters · filed 2022-03-17 | $823.00K derived: sum of 3 quarters · filed 2022-03-17 | $823.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $288.00K 10-Q · filed 2021-11-10 | $319.00K derived: sum of 2 quarters · filed 2021-11-10 | $319.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $31.00K 10-Q · filed 2021-08-12 | $31.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |